<DOC>
	<DOCNO>NCT01600742</DOCNO>
	<brief_summary>Vorinostat potent well tolerate HDAC inhibitor . It report enhance radiosensitivity cancer cell . We hypothesize addition vorinostat WBRT may increase therapeutic efficacy patient brain metastasis .</brief_summary>
	<brief_title>Vorinostat Concurrent Whole Brain Radiotherapy Brain Metastasis</brief_title>
	<detailed_description>Whole brain radiotherapy ( WBRT ) treatment choice majority patient brain metastasis . Although WBRT yield high radiologic response rate ( 27~56 % ) effective palliation neurologic symptom , response duration limit neurologic progression remain main cause death significant number patient . Vorinostat reasonably well tolerate also compel evidence vorinostat may serve radiosensitizer . Preclinical study HDAC inhibition also show efficacy neuron protection . These data suggest addition vorinostat standard therapy WBRT may potentially increase therapeutic efficacy without increase neurotoxicity , support rationale phase II trial vorinostat WBRT patient brain metastasis .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients histologic diagnosis malignancy ( lung breast cancer ) radiologic evidence brain metastasis suitable surgery radiosurgery judge basis lesion size , number , location patient ' personal choice . Patients control systemic disease &gt; 6 week ( judged case case situation ) Age≧20 year Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) ≦3 Life expectancy ≧6 month No prior cranial radiotherapy Negative urine pregnancy test do ≤7 day prior registration , woman childbearing potential . Measurable lesion gadoliniumenhanced MRI contrastenhanced CT scan . ( ≧10mm T1weighted gadolinium enhance MRI contrastenhanced CT ) Patients must adequate organ marrow reserve measure within 7 day prior randomization define : 1 . Hemoglobin &gt; 8.0 gm/dL ; 2 . Absolute neutrophil count &gt; 1,000/mcL ; 3 . Platelets &gt; 100,000/mcL ; 4 . Total bilirubin ≤ 1.5 x UNL ( upper normal limit ) ; 5 . AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x UNL ; patient liver metastasis , AST ( SGOT ) /ALT ( SGPT ) ≤ 5 x UNL allow ; 6 . Serum creatinine ≤ 1.5 x UNL ; 7 . PTT ≤ UNL ; 8 . INR ≤ 1.5 ; 9 . Serum sodium , calcium , potassium , magnesium level within normal limit . Patients ( surrogate ) must able comply study procedure sign inform consent . Prior cranial RT . Known hypersensitivity component vorinostat . Use Valproic acid histone deacetylase inhibitor , ≤2 week prior registration treatment . Uncontrolled infection . Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety adverse event prescribe regimen limit compliance study requirement . History myocardial infarction unstable angina ≤6 month prior registration congestive heart failure ( CHF ) require use ongoing maintenance therapy , lifethreatening ventricular arrhythmia . Inability take oral medication . Receiving investigational agent . Congenital long QT syndrome . Prolonged QTc interval ( &gt; 450 msec ) Any follow Category I drug generally know risk cause Torsades de Pointes ≤7 day prior registration : Quinidine , procainamide , disopyramide , amiodarone , sotalol , ibutilide , dofetilide , erythromycin , clarithromycin , chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine Any following : 1 . Pregnant woman 2 . Nursing woman 3 . Men woman childbearing potential unwilling employ adequate contraception throughout duration study 3 week treatment end .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>